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Abstract 
Background: The Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility 
testing worldwide. The EUCAST guidelines are freely available to users while CLSI is available for non-members as a 
package of three documents for US $500 annually. This is prohibitive for clinical microbiology laboratories in resource 
poor settings. We set out to compare antibiotic susceptibility determined by the two guidelines to determine 
whether adoption of EUCAST guidelines would significantly affect our susceptibility patterns.
Methods: We reviewed minimum inhibitory concentrations (MIC) of various antibiotics routinely reported for 
Escherichia coli (E. coli), Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) isolates from 
an automated microbiology identification system (VITEK-2) at the Aga Khan University Hospital Nairobi’s Pathology 
department. These MICs were then analyzed using both CLSI 2015 and EUCAST 2015 guidelines and classified as 
resistant, intermediate or susceptible. We compared the susceptibility and agreement between the CLSI and EUCAST 
categorizations.
Results: Susceptibility data from a total of 5165 E. coli, 1103 S. aureus and 532 P. aeruginosa isolates were included. 
The concordance rates of the two guidelines for E. coli, S. aureus and P. aeruginosa ranged from 78.2 to 100 %, 94.6 to 
100 % and 89.1 to 95.5 % respectively. The kappa statistics for E. coli MICs revealed perfect agreement between CLSI 
and EUCAST for cefotaxime, ceftriaxone and trimethoprim–sulfamethoxazole, almost perfect agreement for ampicillin, 
ciprofloxacin, cefuroxime, gentamicin and ceftazidime, substantial agreement for meropenem, moderate agreement 
for cefepime and amoxicillin-clavulanate, fair agreement for nitrofurantoin and poor agreement for amikacin. For S. 
aureus the kappa statistics revealed perfect agreement for penicillin, trimethoprim–sulfamethoxazole, levofloxacin, 
oxacillin, linezolid and vancomycin, almost perfect agreement for clindamycin, erythromycin and tetracycline and 
moderate agreement for gentamicin. For P. aeruginosa the kappa analysis revealed moderate to almost perfect agree-
ment for all the anti-pseudomonal antibiotics.
© 2016 Kassim et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Over the last two decades, there has been emergence and 
spread of antibiotic resistance in many bacterial clinical 
pathogens [1]. Categorization of minimum inhibitory 
concentrations (MIC) of various antibiotics in antimicro-
bial susceptibility testing (AST) depends on breakpoints 
set by various international agencies. These breakpoints 
affect clinical decision making by determining whether 
an antibiotic is reported as susceptible or not. One of 
the most popular guidelines used worldwide is from 
the Clinical and Laboratory Standards Institute (CLSI) 
whose interpretive cut offs for antibiotics is based on 
MIC distributions, pharmacokinetic–pharmacodynamic 
(PK-PD) properties and the mechanisms of resistance 
[1]. The adoption of antibiotic susceptibility guidelines in 
the US is regulated by the Food and Drug Administration 
(FDA). In 1997 various national agencies in Europe came 
together to form the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) that has since har-
monized antibiotic interpretive breakpoints throughout 
Europe and most European countries have since switched 
from CLSI and their local guidelines to EUCAST guide-
lines [2, 3]. EUCAST bases its clinical breakpoints on 
epidemiological MIC cut-offs (ECOFFS) and PK-PD 
properties. All documents on MIC distributions and 
ECOFFS are freely available on the EUCAST website [4].
Polsfuss et al. compared EUCAST with CLSI in screen-
ing for extended-spectrum beta-lactamase (ESBL) pro-
ducing Enterobacteriaceae isolates. They found no 
significant difference in the sensitivity of the two guide-
lines in the detection of ESBL-producing isolates [5]. A 
more recent study by Hombach et al. demonstrated sig-
nificant differences in the susceptibility rates for drugs 
including cefepime, ceftazidime and cefotaxime in the 
detection of ESBLs between the CLSI 2013 and EUCAST 
2013 AST guidelines. This study recommended adjust-
ments to the clinical breakpoints to further harmonize 
the two guidelines [6]. Since then 2014 and 2015 guide-
lines for both systems have been released in an effort to 
harmonize the clinical breakpoints [7, 8].
CLSI guidelines have a number of disadvantages. 
First, it is based on annual subscriptions of US $350 for 
members and a cost of US $500 to non-members annu-
ally and this may be a problem for microbiology labora-
tories in resource poor settings. Secondly, details on the 
decision making process are not accessible to the public. 
Thirdly, the FDA has a major influence in determining 
official clinical breakpoints before they are adopted by 
CLSI and this raises major concerns on the influence of 
pharmaceutical industries in establishing the guidelines. 
CLSI has a voting committee comprising representa-
tives of both the profession and the industry and hence 
the industry plays a role in the decision making process. 
As for EUCAST, the industry only plays a consultative 
role and is not allowed to finance or participate in deci-
sion making [3]. EUCAST encourages the formation of 
National Antimicrobial Susceptibility Testing Commit-
tees (NAC) that can send a representative to sit in its 
General Committee (GC) thus fostering inclusivity in the 
decision making process [3]. Finally, antibiotics that are 
not registered in the US may not be included in the CLSI 
guidelines.
For resource poor settings like Africa, there is need for 
guidelines that are accessible and affordable while still 
maintaining quality of reported susceptibility. Given that 
antibiotic susceptibility is quite variable across different 
settings, we set out to compare the susceptibility rates of 
selected antibiotics based on CLSI 2015 and EUCAST 
2015 AST guidelines and the level of agreement between 
the two guidelines.
Methods
The study was carried out at the Aga Khan University 
Hospital, Nairobi’s (AKUHN) Department of Pathology. 
Ethical exemption was granted by the AKUHN’s research 
and ethics committee (Ref 2015/REC-44) since this type 
of study is low risk and classified as a clinical audit. This 
was a retrospective study reviewing the MICs of various 
antimicrobials on one commonly isolated gram posi-
tive organism, Staphylococcus aureus (S. aureus), one 
fermenting gram negative organism, Escherichia coli (E. 
coli) and one non-fermenting gram negative organism, 
Pseudomonas aeruginosa (P. aeruginosa). MIC data for 
E. coli, P. aeruginosa and S. aureus isolates was collected 
from two Vitek 2 (version 4.01, bioMerieux, Marcy-
l’Etoile, France) automated microbiology systems for the 
period January 2012 to December 2014. The Vitek 2 AST-
P580 and AST-GN26/AST-GN83 cards were used for 
antibiotic susceptibility for S. aureus and E. coli/P. aerugi-
nosa respectively. Ceftriaxone MICs were only available 
Conclusion: The results show comparable antibiotic susceptibility patterns between CLSI and EUCAST breakpoints. 
Given that EUCAST guidelines are freely available, it makes it easier for laboratories in resource poor settings to have 
an updated and readily available reference for interpreting antibiotic susceptibilities.
Keywords: European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical Laboratory Standards 
Institute (CLSI), Antimicrobial susceptibility testing (AST), Minimum inhibitory concentrations (MIC)
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for the year 2014 in the AST-GN83 cards for a total of 
1673 E. coli isolates. The data was summarized using 
Microsoft Excel 2013 and imported into IBM (Interna-
tional Business Machines, Corporation; Armonk, New 
York, United States of America) SPSS (Statistical Pack-
age for the Social Sciences) Version 22.0 that was used 
for analysis. The MICs were then analyzed using both 
the CLSI 2015 and EUCAST 2015 guidelines to catego-
rize them as either susceptible, intermediate or resistant 
[7, 8]. The concordance rate between the two guidelines 
in percentage was compared. The susceptibility rates for 
the various antimicrobial agents were also calculated in 
percentages for each organism. Analysis of the extent of 
agreement between CLSI 2015 and EUCAST 2015 for 
the various antimicrobials was carried out using Cohen’s 
kappa statistics and graded from perfect agreement to 
poor agreement [9]. Cohen’s Kappa statistics determines 
the proportion of agreement over and above chance 
between two independent observations. This ranges from 
−1 to 1 and a p value less than 0.05 means that the agree-
ment reported is significantly different from 0 and is not 
due to chance. For all inferential statistics, a p value less 
than 0.05 was considered statistically significant.
Results
A total of 5165 E. coli, 1103 S. aureus and 532 P. aerugi-
nosa non-duplicate isolates were included in the analysis. 
Of the 5165 E. coli MICs analyzed, there was compara-
ble susceptibility to most antibiotics including ampicillin, 
amoxicillin–clavulanate, cefuroxime, cefotaxime, ceftri-
axone, trimethoprim–sulfamethoxazole, ciprofloxacin, 
gentamicin and meropenem between the two guidelines. 
The concordance between the two guidelines ranged 
from 78.2 to 100 %. Table 1 summarizes the susceptibili-
ties, concordance and kappa statistics between the two 
guidelines for E. coli.
The E. coli susceptibility patterns achieved after anal-
ysis using EUCAST 2015 and CLSI 2015 guidelines are 
similar except for amoxicillin–clavulanate, amikacin and 
nitrofurantoin. Analysis year by year did not show any 
difference in the trends and overall susceptibilities. The 
kappa analysis revealed perfect agreement for ceftriax-
one, cefotaxime and trimethoprim–sulfamethoxazole 
with kappa (κ) of 1 (p < 0.000). An almost perfect agree-
ment was noted with ampicillin κ = 0.985 (95 % CI 0.979, 
0.991), p < 0.000, ciprofloxacin κ = 0.969 (95 % CI 0.963, 
0.975), p < 0.000, cefuroxime κ = 0.924 (95 % CI 0.914, 
0.934), p < 0.000, ceftazidime κ = 0.859 (95 % CI 0.843, 
0.85), p < 0.000 and gentamicin κ = 0.979 (95 % CI 0.973, 
0.985), p < 0.000. Substantial agreement was noted with 
meropenem κ = 0.724 (95 % CI 0.573, 0.875), p < 0.000 
while moderate agreement was noted with amoxicillin-
clavulanate κ =  0.581 (95  % CI 0.567, 0.595), p  <  0.000 
and cefepime κ = 0.600 (95 % CI 0.578, 0.622), p < 0.000. 
Fair agreement was seen with nitrofurantoin κ =  0.351 
(95  % CI 0.314, 0.388), p  <  0.000 while poor agreement 
was noted with amikacin κ  =  0.112 (95  % CI 0.079, 
0.145), p < 0.000.
Of the 1103 S. aureus MICs analyzed, susceptibility 
to penicillin, oxacillin, levofloxacin, linezolid, trimetho-
prim–sulfamethoxazole, vancomycin, clindamycin, 
erythromycin and tetracycline was comparable between 
Table 1 Susceptibilities of E. coli to various antibiotics, concordance and kappa statistics between CLSI 2015 and EUCAST 
2015 guidelines
Amox-Clav amoxicillin–clavulanate, TMP/SMX trimethoprim–sulfamethoxazole, S susceptible, I intermediate, R resistant
Antibiotic CLSI (%); n = 5165 EUCAST (%); n = 5165 Concordance (%) Kappa, κ (95 % CI)
S I R S I R
Ampicillin 13.8 0.5 85.7 13.8 0 86.2 99.5 0.985 (0.979, 0.991)
Amox-Clav 55.8 23.8 20.4 55.8 0 44.2 78.2 0.581 (0.567, 0.595)
TMP/SMX 0 0 100 0 0 100 100 1
Nitrofurantoin 84.6 11.9 3.5 96.5 0 3.5 87.6 0.351 (0.314, 0.388)
Ciprofloxacin 57.3 0.2 42.5 55.9 1.4 42.7 98.4 0.969 (0.963, 0.975)
Cefuroxime 63.7 3.5 32.8 63.7 0 36.3 96.5 0.924 (0.914, 0.934)
Gentamicin 78.5 0.2 21.3 78.1 0.4 21.5 99.5 0.979 (0.973, 0.985)
Amikacin 99.3 0.3 0.4 90.5 8.8 0.7 91.1 0.112 (0.079, 0.145)
Cefotaxime 69.7 0.4 29.9 69.7 0.4 29.9 100 1
Ceftazidime 76.3 0.9 22.8 71.5 4.8 23.7 93.7 0.859 (0.843, 0.85)
Ceftriaxone 67.7 0.1 32.2 67.7 0.1 32.2 100 1
Cefepime 80.5 10.0 9.5 72.9 9.8 17.3 84.9 0.600 (0.578, 0.622)
Meropenem 99.7 0.1 0.2 99.8 0.1 0.1 99.7 0.724 (0.573, 0.875)
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the two guidelines. The susceptibilities, concordance and 
kappa statistics between the two guidelines are shown in 
Table 2.
For S. aureus the susceptibilities are generally very 
similar between the two guidelines. Year by year analy-
sis did not show any differences in trends and suscepti-
bility patterns. The kappa analysis for CLSI 2015 and 
EUCAST 2015 guidelines revealed perfect agreement for 
levofloxacin, linezolid, vancomycin, oxacillin, penicillin 
and trimethoprim–sulfamethoxazole with a kappa sta-
tistic of 1 (p < 0.000). An almost perfect agreement was 
noted with clindamycin κ = 0.904 (95 % CI 0.826, 0.982), 
p < 0.000, erythromycin κ = 0.978 (95 % CI 0.960, 0.996), 
p  <  0.000 and tetracycline κ  =  0.962 (95  % CI 0.940, 
0.984), p  <  0.000. Moderate agreement was noted with 
gentamicin κ = 0.537 (95 % CI 0.441, 0.633), p < 0.000.
For the 532 P. aeruginosa analyzed there were similar 
susceptibility patterns noted between CLSI 2015 and 
EUCAST 2015. Antibiotics analyzed included amikacin, 
ceftazidime, ciprofloxacin, cefepime, gentamicin, mero-
penem and piperacillin–tazobactum. The susceptibili-
ties, concordance and kappa statistics between the two 
guidelines are shown in Table 3. Year by year analysis did 
not show any differences in trends and susceptibility pat-
terns. The kappa analysis for CLSI 2015 and EUCAST 
2015 guidelines revealed moderate to almost perfect 
agreement for all the anti-pseudomonal antibiotics. P 
values for the kappa statistics for all the antibiotics were 
statistically significant at p < 0.000. Overall, the antibiotic 
susceptibility patterns were quite similar regardless of 
whether CLSI or EUCAST 2015 guidelines were used.
Discussion
The morbidity and mortality associated with communi-
cable diseases including bacterial infections is quite sig-
nificant in developing countries [10]. Antibiotics play a 
critical role in treating such infections especially when 
instituted in a timely fashion more so when the bacteria 
Table 2 Susceptibilities of S.aureus to various antibiotics and the concordance and kappa statistics between CLSI 2015 
and EUCAST 2015 guidelines
TMP/SMX trimethoprim–sulfamethoxazole, S susceptible, I intermediate, R resistant
Antibiotic CLSI (%); n = 1103 EUCAST (%); n = 1103 Concordance (%) Kappa, κ (95 % CI)
S I R S I R
Penicillin 10.6 0 89.4 10.6 0 89.4 100 1
TMP/SMX 0 0 100 0 0 100 100 1
Clindamycin 98.0 0.3 1.7 98.0 0.1 1.9 99.5 0.904 (0.826, 0.982)
Erythromycin 85.6 0.5 13.9 86.0 0 14.0 99.4 0.978 (0.960, 0.996)
Gentamicin 96.3 0.5 3.2 91.5 0 8.5 94.6 0.537 (0.441, 0.633)
Levofloxacin 90.8 0.3 8.9 90.8 0.3 8.9 100 1
Linezolid 100 0 0 100 0 0 100 1
Oxacillin 93.3 0 6.7 93.3 0 6.7 100 1
Tetracycline 83.2 0.1 16.7 82.4 0.8 16.8 98.9 0.962 (0.940, 0.984)
Vancomycin 100 0 0 100 0 0 100 1
Table 3 Susceptibilities of  P.aeruginosa to  various antibiotics and  the concordance and  kappa statistics between  CLSI 
2015 and EUCAST 2015 guidelines
Pip-Taz piperacillin–tazobactum, CI confidence interval, S susceptible, I intermediate, R resistant
CLSI (%); n = 532 EUCAST (%); n = 532 Concordance (%) Kappa, κ (95 % CI)
S I R S I R
Amikacin 79.5 3.0 17.5 72.2 7.3 20.5 89.7 0.734 (0.703; 0.765)
Ceftazidime 70.9 4.7 24.4 70.9 0 29.1 95.3 0.890 (0.870; 0.910)
Cefepime 72.6 4.7 22.7 72.6 0 27.4 95.3 0.886 (0.866; 0.906)
Gentamicin 72.6 6.2 21.2 72.6 0 27.4 93.8 0.851 (0.829; 0.873)
Meropenem 64.1 8.3 27.6 64.1 12.8 23.1 95.5 0.912 (0.895; 0.929)
Pip-taz 64.5 8.3 27.3 64.5 0 35.5 91.7 0.830 (0.808; 0.852)
Ciprofloxacin 71.8 5.3 22.9 66.2 5.6 28.2 89.1 0.762 (0.736; 0.788)
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is susceptible to the antibiotic given. The determina-
tion of accurate antibiotic susceptibility is therefore an 
important cog in the clinical care of bacterial infections 
especially in organisms that possess acquired resistance 
mechanisms and careful consideration should be given 
when deciding how to interpret phenotypic susceptibil-
ity data [11]. In Kenya, many laboratories have adopted 
CLSI guidelines as a basis for interpreting their suscep-
tibility data despite the fact that it costs between US 
$300–$500. These guidelines are updated annually and 
therefore require laboratories to keep on purchasing 
them at a cost that is prohibitive to most public labo-
ratories. Failure to stay updated may result in misinter-
pretation of susceptibility. For example in 2013, CLSI 
abandoned the use of oxacillin disc diffusion in determin-
ing whether a S. aureus isolate is methicillin resistant in 
favour of cefoxitin because it was more accurate in deter-
mining the presence of a mecA mediated mechanism of 
resistance [12]. In 2012, it adopted a new disc diffusion 
susceptibility cut off for ciprofloxacin of 31 mm up from 
21  mm for non-typhoidal Salmonella (NTS) isolated 
from invasive specimens and all Salmonella Typhi iso-
lated from both invasive and non-invasive specimens. 
The MIC for the same was reduced from 1 to 0.06 μg/mL 
resulting in many Salmonella spp. previously reported 
as susceptible to fall into the intermediate category, and 
many that were intermediate were now categorized as 
resistant [13]. In 2013, CLSI recommended that these cut 
offs should apply to all Salmonella spp. including NTS 
from non-invasive specimens [12, 14]. In the same year 
new levofloxacin and ofloxacin breakpoints were intro-
duced for Salmonella spp. including Salmonella Typhi. 
These changes were motivated by an increased risk of 
treatment failure in patients with decreased ciprofloxa-
cin susceptible Salmonella spp [15]. In 2012 again, CLSI 
reduced meropenem and piperacillin-tazobactum MIC 
breakpoints for P. aeruginosa from  ≤4 to  ≤2  ug/mL 
and  ≤64  ug/mL to  ≤16  ug/mL respectively [13]. These 
examples highlight the importance of remaining up-to-
date and emphasizes the need for an affordable, up-to-
date and readily available guideline for the interpretation 
of antibiotic susceptibility.
In our comparison of CLSI and EUCAST guidelines 
for interpretation of antibiotic susceptibility, for E. coli, 
most of the antibiotics had moderate to perfect agree-
ment between the two guidelines with kappa values 
ranging from 0.581 to 1 and two-thirds of them having 
almost perfect or perfect agreement with kappa values 
ranging from 0.859 to 1. Poor agreement was noted with 
amikacin with EUCAST having a more stringent break-
point for susceptibility of ≤8 mg/L compared to the CLSI 
breakpoint of  ≤16  mg/L. The major discrepancy was 
in the intermediate and susceptible categories as 8.8  % 
of isolates labeled as intermediate by EUCAST were all 
categorized as susceptible by CLSI. EUCAST guidelines 
eliminated the intermediate category for some antibiot-
ics and this explains the reduced level of agreement for 
some of the antibiotics. For example, CLSI categorized 
23.8 % of E. coli as having intermediate susceptibility to 
amoxicillin-clavulanate but were all categorized as resist-
ant by EUCAST while 11.9 % categorized as intermediate 
susceptibility to nitrofurantoin by CLSI were categorized 
as susceptible by EUCAST. From a clinical stand point, 
reclassifying amoxicillin-clavulanate from intermedi-
ate to resistant is unlikely to adversely affect the patient 
as it simply removes it from being a therapeutic consid-
eration. As for nitrofurantoin, its ability to concentrate 
in urine enables it to achieve significant concentrations 
and eliminate isolates that may have intermediate sus-
ceptibility. Therefore, the reclassification of isolates that 
are intermediate by CLSI to susceptible by EUCAST is 
unlikely to contribute to adverse outcomes for patients 
with urinary tract infections. The EUCAST guidelines 
have slightly more stringent breakpoints for some antibi-
otics in an effort to curb the inappropriate use of antibi-
otics and control the rising rates of antibiotic resistance.
For S. aureus, all except one of the antibiotics had mod-
erate to perfect agreement and three quarters of them 
had almost perfect or perfect agreement with kappa 
values ranging from 0.862 to 1. The two guidelines per-
formed equally in the detection of the rate of methicillin 
resistant Staphylococcus aureus (MRSA) of 7.2  %. Van-
comycin susceptible Staphylococcus aureus (VSSA) were 
also detected equally by the two guidelines. EUCAST 
eliminated the intermediate category for vancomycin 
in a bid to discourage the reporting of Glycopeptide-
intermediate Staphylococcus aureus (GISA) due to poor 
response even to increased doses of vancomycin [8, 16]. 
In view of the fact that no vancomycin resistant Staphy-
lococcus aureus (VRSA) has been identified in our set up 
as yet, these changes are unlikely to influence interpre-
tation of breakpoints. The moderate level of agreement 
for gentamicin is due to the more stringent breakpoints 
by EUCAST leading to a much higher resistance rate of 
8.6 % compared to 3.2 % by CLSI. The difference between 
the two susceptibility cut-offs is two dilutions and this 
may require further harmonization. Gentamicin is rarely 
used as monotherapy in treating gram positive bacteria 
and as such this difference in MIC cut off is unlikely to be 
clinically significant.
For P. aeruginosa, five out of seven of the antibiotics 
had almost perfect agreement with kappa values ranging 
from 0.830 to 0.912 with the remaining two having mod-
erate agreement with kappa values of 0.762 and 0.734. 
EUCAST abolished the intermediate category for ceftazi-
dime, cefepime, gentamicin and piperacillin-tazobactum 
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reclassifying the MICs as resistant. This accounts for 
the slightly reduced level of agreement. For amikacin 
and ciprofloxacin, with moderate agreement, EUCAST 
has more stringent breakpoints for susceptibility of  ≤8 
and ≤0.5  ug/mL compared to CLSI breakpoints of ≤16 
and  ≤1  ug/mL respectively. These accounted for the 
reduced level of agreement and may require further 
harmonization between the two breakpoints. For mero-
penem, EUCAST uses a resistant breakpoint of  >8  ug/
mL while CLSI uses ≥8 ug/mL. In effect this has led to 
a slightly higher meropenem resistance of 27.6  % com-
pared to 23.1 % for CLSI and EUCAST respectively. This 
is another aspect that will require harmonization.
Our study is limited by the fact that we only compared 
the susceptibility for three bacteria whose results may not 
necessarily be generalizable to all clinically relevant gram 
positive and negative bacteria. However, these three bac-
teria represent a significant proportion of common bac-
terial pathogens both in the community and healthcare 
settings namely Enterobacteriaceae, non-fermenting 
gram negative bacteria and Staphylococci. The results 
obtained are also limited to MICs generated by an auto-
mated bacterial identification system which is not widely 
used in developing countries. For P. aeruginosa, Colis-
tin had not yet been included in the gram negative AST 
cards being used at the time the study was being con-
ducted. Colistin Etest® (bioMerieux, Durham, NC, USA) 
was only run for multi-drug resistant isolates of clinical 
significance but this data was not available for analysis. 
In most laboratories in sub-Saharan Africa, disk diffusion 
is the preferred mode of antibiotic susceptibility testing. 
However, disk diffusion cut offs generally approximate 
MIC cut offs fairly well and we think a similar compari-
son based on disc diffusion cut offs would yield similar 
results.
Conclusion
Our study shows acceptable level of agreement between 
EUCAST and CLSI 2015 AST guidelines for E. coli, S. 
aureus and P. aeruginosa and laboratories with similar 
antibiotic susceptibility patterns may choose to adopt 
either guideline without fear of significantly altering 
reported antibiotic susceptibility. With EUCAST guide-
lines being freely available it should be considered as 
an alternative especially in resource poor settings in 
order to maintain up-to-date antibiotic susceptibility 
interpretation.
Abbreviations
AKUHN: Aga Khan University Hospital, Nairobi; Amox-Clav: amoxicillin–cla-
vulanate; AST: antimicrobial susceptibility testing; CLSI: Clinical Laboratory 
Standards Institute; ECOFFS: epidemiological cut-offs; ESBL: extended 
spectrum beta lactamase; Etest: epsilometer test; EUCAST: European Com-
mittee on Antimicrobial Susceptibility Testing; E. coli: Escherichia coli; FDA: 
Food and Drug Administration; GC: General Committee; GISA: Glycopeptide-
intermediate Staphylococcus aureus; IBM: International Business Machines 
Corporation (Armonk, New York, United States of America); MIC: minimum 
inhibitory concentration; MRSA: methicillin resistant Staphylococcus aureus; 
NAC: National Antimicrobial Susceptibility Testing Committees; NTS: non-
typhoidal salmonella; Pip-Taz: piperacillin–tazobactum; PK-PD: pharmacoki-
netic–pharmacodynamics; SPSS: statistical package for the social sciences; S. 
aureus: Staphylococcus aureus; TMP/SMX: trimethoprim–sulfamethoxazole; US 
$: United States of America dollar; VRSA: vancomycin resistant Staphylococcus 
aureus; VSSA: vancomycin susceptible Staphylococcus aureus.
Authors’ contributions
AK and GO contributed equally in conceiving and designing the study, data 
collection, data analysis and drafting the manuscript. ZP and GR participated 
in study design, coordination and critical revision of the manuscript. All 
authors read and approved the final manuscript.
Acknowledgements
None.
Competing interests
The authors declare that they have no competing interests.
Received: 22 January 2016   Accepted: 25 March 2016
References
 1. Marchese A, Esposito S, Barbieri R, Bassetti M, Debbia E. Does the adop-
tion of EUCAST susceptibility breakpoints affect the selection of antimi-
crobials to treat acute community-acquired respiratory tract infections? 
BMC Infect Dis. 2012;12(1):181.
 2. EUCAST. http://www.eucast.org/. Accessed 31 Aug 2015.
 3. Kahlmeter G. The 2014 Garrod Lecture: EUCAST—are we heading towards 
international agreement? J Antimicrob Chemother. 2015;70(9):2427–39. 
http://www.jac.oxfordjournals.org/lookup/doi/10.1093/jac/dkv145.
 4. Wolfensberger A, Sax H, Weber R, Zbinden R, Kuster SP, Hombach M. 
Change of antibiotic susceptibility testing guidelines from CLSI to 
EUCAST: influence on cumulative hospital antibiograms. PLoS One. 
2013;8(11):1–8.
 5. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. Comparison of 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
and CLSI screening parameters for the detection of extended-spectrum 
β-lactamase production in clinical enterobacteriaceae isolates. J Antimi-
crob Chemother. 2011;2012(67):159–66.
 6. Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI 
and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and 
AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. J 
Antimicrob Chemother. 2013;68:2092–8.
 7. CLSI. M100-S25 performance standards for antimicrobial susceptibility 
testing; Twenty-fifth informational supplement; 2015.
 8. EUCAST: European Committee on Antimicrobial Susceptibility Testing 
breakpoint tables for interpretation of MICs and zone diameters. 2015. 
http://www.eucast.org/fileadmin/src/media/PDFs/EUC.
 9. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa 
statistic. Fam Med. 2005;37(5):360–3.
 10. GBD_report_2004update_full.pdf. http://www.who.int/healthinfo/
global_burden_disease/GBD_report_2004update_full.pdf. Accessed 22 
Dec 2015.
 11. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review 
of general principles and contemporary practices. Clin Infect Dis. 
2009;49(11):1749–55.
 12. CLSI. M100-S23 performance standards for antimicrobial susceptibility 
testing; twenty-third informational supplement; 2013.
 13. CLSI. M100-S22: performance standards for antimicrobial susceptibil-
ity testing; twenty-second informational supplement—M100S22E.pdf. 
http://www.antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/
M100S22E.pdf. Accessed 22 Dec 2015.
Page 7 of 7Kassim et al. Ann Clin Microbiol Antimicrob  (2016) 15:21 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 14. Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility 
testing of fluoroquinolone activity against Salmonella: recent changes to 
CLSI standards. Clin Infect Dis. 2012;55(8):1107–13.
 15. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, et al. Clini-
cal response and outcome of infection with Salmonella enterica serotype 
typhi with decreased susceptibility to fluoroquinolones: A United States 
FoodNet multicenter retrospective cohort study. Antimicrob Agents 
Chemother. 2008;52(4):1278–84.
 16. Uçkay I, Bernard L, Buzzi M, Harbarth S, François P, Huggler E, et al. High 
prevalence of isolates with reduced glycopeptide susceptibility in 
persistent or recurrent bloodstream infections due to methicillin-resistant 
Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56(3):1258–
64. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3294919
&tool=pmcentrez&rendertype=abstract.
